---
title: 'EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate
  clinical endpoint for multiple myeloma'
date: '2024-05-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38768337/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240521183404&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Estimating progression-free survival (PFS) and overall survival (OS)
  superiority during clinical trials of multiple myeloma (MM) has become increasingly
  challenging as novel therapeutics have improved patient outcomes. Thus, it is imperative
  to identify earlier endpoint surrogates that are predictive of long-term clinical
  benefit to expedite development of more effective therapies. Minimal residual disease
  (MRD)-negativity is a common intermediate endpoint that has shown prognostic value
  ...
disable_comments: true
---
Estimating progression-free survival (PFS) and overall survival (OS) superiority during clinical trials of multiple myeloma (MM) has become increasingly challenging as novel therapeutics have improved patient outcomes. Thus, it is imperative to identify earlier endpoint surrogates that are predictive of long-term clinical benefit to expedite development of more effective therapies. Minimal residual disease (MRD)-negativity is a common intermediate endpoint that has shown prognostic value ...